Related Experiment Videos
Cyclosporine as a milestone in immunosuppression
1Department of Surgery, Douglas House Annexe, Cambridge, UK. cpr100@cam.ac.uk
Transplantation Proceedings
|March 26, 2004
Summary
Cyclosporine significantly improved 1-year organ allograft survival rates, increasing success from 50% to 80%. Despite later challenges like nephrotoxicity, it remains a vital immunosuppressive drug for transplant patients.
Area of Science:
- Immunology
- Nephrology
- Transplantation Medicine
Background:
- Organ allografting faced high failure rates before targeted immunosuppression.
- Pre-cyclosporine era immunosuppression, including azathioprine and steroids, resulted in a 50% 1-year graft failure rate, particularly in kidney transplants.
Purpose of the Study:
- To review the role and impact of cyclosporine in organ allograft immunosuppression.
- To assess the evolution of immunosuppressive strategies and cyclosporine's place within them.
Main Methods:
- Review of historical data and clinical outcomes in organ transplantation.
- Analysis of graft survival rates and patient function with different immunosuppressive regimens.
Main Results:
- Cyclosporine dramatically improved 1-year graft survival from 50% to 80%.
- While 10-year survival showed less difference compared to azathioprine and steroids, cyclosporine preserved kidney function in many patients.
- Late graft failure was often linked to cyclosporine-induced nephrotoxicity from calcineurin inhibition.
Conclusions:
- Cyclosporine revolutionized early graft survival in organ transplantation.
- Understanding and managing cyclosporine's nephrotoxicity has led to improved therapeutic strategies.
- Cyclosporine continues to be an essential immunosuppressive agent for managing organ allograft recipients.